DEF: CDT Equity Inc. Schedules Virtual Annual Meeting

CDT Equity Inc. announced its 2026 virtual annual meeting of stockholders, detailing proposals including director elections, auditor ratification, reverse stock splits, and share issuances.

Summary

• CDT Equity Inc. is holding its 2026 virtual annual meeting of stockholders on August 28, 2026.
• Key proposals include the election of five directors, ratification of Carr, Riggs & Ingram, L.L.C. as the independent auditor for fiscal year 2026, and approval of one or more reverse stock splits.
• The reverse stock split ratio can range from 1-for-2 to 1-for-100 per split, with an aggregate not exceeding 1-for-500.
• The meeting will also vote on the issuance of common stock related to a senior secured convertible note and common stock purchase warrant issued to J.J. Astor & Co., and the issuance of shares upon exercise of pre-funded warrants.
• Stockholders of record as of August 3, 2026, are entitled to vote.
• The company is also addressing past Section 16(a) filing delinquencies for certain individuals and entities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as cautiously optimistic, with significant proposals for restructuring and financing that could benefit the company if successful, but also carrying inherent risks.

Positives

• The company is proactively addressing potential future Nasdaq listing requirements through proposed reverse stock splits.
• The appointment of a new independent auditor, Carr, Riggs & Ingram, L.L.C., suggests a move towards financial oversight.
• The company is seeking to approve share issuances that could facilitate financing and strategic partnerships.
• The virtual meeting format allows for broader stockholder participation.
• The company has a clear slate of director nominees with diverse experience.

Negatives

• The company has a history of delinquent Section 16(a) filings, indicating potential internal control or compliance issues.
• The proposed reverse stock splits carry risks of not increasing the stock price and potentially reducing liquidity.
• The issuance of shares related to convertible notes and warrants could lead to significant dilution for existing shareholders.
• The company's financial stability is implicitly questioned by the need for reverse stock splits to maintain Nasdaq listing.

Risks

• The reverse stock split may not achieve its intended effect of increasing the stock price or attracting investors.
• The issuance of new shares could significantly dilute existing shareholders' ownership and earnings per share.
• Failure to obtain stockholder approval for the proposed actions could hinder the company's strategic and financial plans.
• The company has experienced past issues with Section 16(a) filings, suggesting potential ongoing compliance challenges.
• The company's reliance on financing through convertible notes and warrants indicates a need for capital, which may not be guaranteed.

Future Outlook

The company is seeking stockholder approval for several key proposals, including reverse stock splits and share issuances, which are intended to improve its financial standing, maintain Nasdaq listing, and potentially attract investment. The success of these initiatives will significantly shape the company's future outlook.

Management Comments

• Stockholders are urged to vote by using the Internet or by executing and returning the enclosed proxy card.
• The Board believes the separation of Chairperson and CEO roles, with Ms. Chiavacci Farley as Chairperson and Dr. Regan as CEO, serves the company well.
• The Board recommends voting FOR each of the director nominees, FOR the ratification of the independent auditor, FOR the reverse stock splits, FOR the share issuances related to J.J. Astor & Co., FOR the pre-funded warrants, and FOR the adjournment of the meeting if necessary.

Industry Context

StockSavvy.ai notes that reverse stock splits are often employed by companies facing delisting due to low share prices, a common challenge in certain market conditions. The proposed share issuances for financing are also typical for companies seeking to fund operations or growth initiatives.

Corporate Governance

Legal Proceedings

• The company mentions ongoing litigation related to Conduit Pharmaceuticals Limited (CPL) in the context of its sale to Corvus Capital Limited.

Related Party Transactions

• Director travel expenses paid to Dr. Andrew Regan (CEO) totaling approximately $0.4 million for 2025 and $0.4 million for 2024.
• Sale of Conduit Pharmaceuticals Limited (CPL) to Corvus Capital Limited (owned by Dr. Andrew Regan) for $7,000,000 satisfied through stock and pre-funded warrants.
• August 2024 Senior Secured Promissory Note with Nirland, amended to allow conversion into common stock at $10 per share, with a 2.25x conversion amount multiplier; note has been repaid.
• October 2024 promissory note to Nirland for $0.6 million, repaid in December 2024.
• Services Agreement with Sarborg Limited for technology services, incurring $1.8 million in milestone payments and $0.4 million in ongoing fees in 2025.
• Additional license and use agreement with Sarborg for analysis of acquired assets, with $2.0 million in aggregate payment, partially prepaid with shares.
• Second Addendum to Sarborg Additional Agreement for integration of a Cryptocurrency AI Agent, with $0.2 million paid in Q3 2025 and $0.2 million paid in Q4 2025.
• Securities Purchase Agreement with Sarborg stockholders to acquire 20% of Sarborg for $8 million cash (deferred) and shares/warrants.
• Joint Development Agreement with Manoira (controlled by Dr. Andrew Regan) for evaluating CDT Assets in animal health, with CDT issuing 77 shares as consideration.

Stakeholder Impact

• Shareholders may experience dilution from proposed share issuances.
• Shareholders may benefit from a potential increase in stock price due to reverse stock splits, but also face risks of reduced liquidity.
• Employees may be affected by compensation adjustments and the company's overall financial health.
• The company's auditors (CBIZ CPAs and Marcum LLP) have been replaced, impacting the audit process and financial reporting oversight.

Next Steps

• Stockholders to vote on the proposals at the virtual annual meeting on August 28, 2026.
• If approved, the Board will determine the specific reverse stock split ratios and filing dates.
• The company will proceed with share issuances as approved by stockholders.
• The company will engage Carr, Riggs & Ingram, L.L.C. as its independent registered public accounting firm for fiscal year 2026.

Key Dates

Recommendation

The company is proposing significant structural changes, including reverse stock splits and share issuances, which carry both potential benefits and substantial risks. While these actions aim to improve financial health and Nasdaq compliance, the potential for dilution and the unproven success of reverse splits warrant a cautious 'hold' approach until the outcomes of these proposals become clearer.

Keywords

Annual Meeting, Proxy Statement, Reverse Stock Split, Director Election, Independent Auditor, Convertible Note, Warrants, Shareholder Approval